KBC Securities - MAAT PHARMA SA (MAAT) MaaT Pharma FIRST LOOK: Positive DSMB review for lead product MaaT013 in aGvHD

Report

KBC Securities

Jacob Mekhael

MaaT Pharma FIRST LOOK: Positive DSMB review for lead product MaaT013 in aGvHD

MaaT announced that the independent data safety monitoring board (DSMB) completed its final safety assessment of the pivotal phase 3 (ARES) trial of MaaT013 in 3L aGvHD, which was in line with previous evaluations confirming the favourable benefit/risk ratio of the product. As a reminder, MaaT013 met its primary endpoint in the phase 3 (ARES) trial, and results presented in January 2025 demonstrated a 28 day GI-ORR of 62%, which came in above expectations. Looking ahead, we look forward to the regulatory submission in the EU planned for June 2025. We reiterate our € 18 TP and Buy rating.

19/03/2025 1 EN

Underlying

MAAT PHARMA SA

See profile

FR0012634822 Euronext Paris France

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

KBC Securities

MaaT Pharma Positive DSMB safety analysis for MaaT033 phase 2 in allo-HSCT

MaaT announced the positive outcome of a key DSMB safety interim analysis for the phase 2b trial (PHOEBUS), which compares the efficacy and safety of MaaT033 (microbiome therapy, oral capsule) to placebo in patients undergoing an allogeneic hematopoietic stem cell transplantation (allo-HSCT). We are encouraged by the DSMB outcome, particularly in the context that allo-HSCT is a high risk patient population, and see this as supportive of MaaT033´s good safety profile. We note that MaaT033 is next in line after lead product MaaT013 in aGvHD, and offers scalability via its oral administration all...

April 8, 2025 April 8, 2025 1 EN

KBC Securities

MaaT Pharma To present preclinical data on MaaT034 at AACR

MaaT will present new non-clinical data on MaaT034 (donor independent microbiome therapy) at the American Association for Cancer Research (AACR) conference, taking place on 25-30 April. The results demonstrate MaaT034's potential as a combination therapy to improve responses to checkpoint inhibitors in solid tumours. Being co-cultured means MaaT034 is donor-independent, which offers the scale required for the larger solid tumour market. Initial data from the phase 2 placebo-controlled trial of lead product MaaT013 (donor dependent) in combination with checkpoint inhibitors in metastatic melano...

April 1, 2025 April 1, 2025 1 EN

KBC Securities

Morning Notes : COLR BB, FLOB BB, KIN BB, MAAT FP, ONWD BB

: COLR BB, FLOB BB, KIN BB, MAAT FP, ONWD BB

April 1, 2025 April 1, 2025 1 EN

Heineken Feedback conference call

Below are the highlights of the conference call. As previously hinted at, Heineken did report a fairly weak 1Q trading update with beer volumes down 2.1%, impacted ao by the timing of Easter, Tet and one trading day less. Importantly, Heineken did stick to its FY25 guidance range of 4-8% organic operating profit (beia) growth. We still appreciate Heineken for the earnings recovery potential in coming years, supported by sizeable cost savings initiatives (€ 400m/y). We maintain our Accumulate rating and € 100 target price.

April 16, 2025 April 16, 2025 1 EN

Wim Hoste

Wim Hoste

Heineken FIRST LOOK: 1Q beer volume -2.1%, FY guidance maintained

As previously hinted at, Heineken did report a fairly weak 1Q trading update with beer volumes down 2.1%, impacted ao by the timing of Easter, Tet and one trading day less. Importantly, Heineken did stick to its FY25 guidance range of 4-8% organic operating profit (beia) growth. We still appreciate Heineken for the earnings recovery potential in coming years, supported by sizeable cost savings initiatives (€ 400m/y). We maintain our Accumulate rating and € 100 target price.

April 16, 2025 April 16, 2025 1 EN

Thibault Leneeuw

Thibault Leneeuw

ASML Weaker order intake, disappointing 2Q25 outlook, strong GPm

ASML 1Q25 revenues were in line with expectation and EPS was better than expected. However, the order intake and 2Q25 outlook are below CSS. The EPS outperformance in 1Q25 was driven by the strong GPm. ASML sold more expensive EUV tools at a richer configuration and due to the fact that they met customer-specific performance targets. The outlook for 2025 remains unchanged. If uncertainties continue ASML sees FY25 revenues at the low end of the guided € 30-35bn range. AI demand could drive the high end of the range although we expect FY25 revenues closer to the low end of the range as we expect...

April 16, 2025 April 16, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MaaT Pharma FIRST LOOK: Positive DSMB review for lead product MaaT013 in aGvHD

We are a financial services provider for several types of professional clients, each with distinct needs.

MaaT Pharma Positive DSMB safety analysis for MaaT033 phase 2 in allo-HSCT

MaaT Pharma To present preclinical data on MaaT034 at AACR

Morning Notes : COLR BB, FLOB BB, KIN BB, MAAT FP, ONWD BB

Heineken Feedback conference call

Heineken FIRST LOOK: 1Q beer volume -2.1%, FY guidance maintained

ASML Weaker order intake, disappointing 2Q25 outlook, strong GPm

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe